Bone density changes in women who receive thromboprophylaxis in pregnancy
Bone density changes in women who receive thromboprophylaxis in pregnancy
复制标题
DOI：
10.1016/j.ajog.2006.06.080
复制
发表时间：
2006-10-01
影响因子：
9.8
通讯作者：
Carson, Michael
中科院分区：
文献类型：
--
作者：
Casele, Holly;Haney, Elaine I.;Carson, Michael
目的：本研究的目的是比较普通肝素治疗与低分子量肝素、依诺肝素钠治疗，以及它们在妊娠过程中对骨密度的影响。这项前瞻性随机对照试验招募了需要血栓预防的妊娠患者，并将其分配接受普通肝素治疗或低分子量肝素治疗，骨密度测定双能X线吸收法在股骨近端的登记，并再次后不久deliver.Results：一百二十名妇女参加，98名妇女完成了这项研究。两组间股骨颈（P = 0.054）或股骨近端（P = 0.584）的骨密度变化无差异。40个病人中只有1个（2.5%）接受普通肝素治疗，49例患者中有I（2.0%）接受低分子量肝素治疗（P = 1.0）股骨颈骨质流失>= 10%。结论：在本研究中，在妊娠期接受血栓预防的女性中，股骨临床显著性骨丢失（>= 10%）的发生率约为2%至2.5%，并且似乎相似，无论患者接受低分子量肝素治疗还是普通肝素治疗。(c)2006 Mosby，Inc. All rights reserved.
Objective: The purpose of this study was to compare unfractionated heparin therapy to the low molecular weight heparin, enoxaparin sodium, and their effects on bone mineral density over the course of pregnancy.Study design: Pregnant patients whose condition required thromboprophylaxis were recruited in this prospective randomized controlled trial and were assigned to receive either unfractionated heparin therapy or low molecular weight heparin therapy, Bone mineral density was measured by dual energy x-ray absorptiometry at the proximal femur on enrollment and again shortly after delivery.Results: One hundred twenty women were enrolled, and 98 women completed the study. There was no difference in the change in bone mineral density at the femoral neck (P = .054) or total proximal femur (P = .584) between groups. Only I of 40 patients (2.5%) who received unfractionated heparin therapy and I of 49 patients (2.0%) who received low molecular weight heparin therapy (P = 1.0) experienced bone loss of >= 10% at the femoral neck.Conclusion: In this study, the incidence of clinically significant bone loss (>= 10%) in the femur in women who received thromboprophylaxis in pregnancy is approximately 2% to 2.5% and appears to be similar, regardless of whether the patient receives low molecular weight heparin therapy or unfractionated heparin therapy. (c) 2006 Mosby, Inc. All rights reserved.